Cletus Arciero1,2, Yuan Liu2,3, Theresa Gillespie1,2, Preeti Subhedar1,2. 1. Emory University School of Medicine, Atlanta, Georgia. 2. Winship Cancer Institute, Atlanta, Georgia. 3. Rollins School of Public Health, Emory University, Atlanta, Georgia.
Abstract
BACKGROUND: Retrospective studies have shown some improvement in survival for patients receiving surgical management of the intact primary tumor in patients with presenting with Stage IV disease, while prospective studies have revealed mixed results. METHODS: An examination of the NCDB from 2004-2013 was undertaken to examine factors related to the utilization of surgery and overall survival in patients with de novo Stage IV disease. Univariate and multivariable analyses were conducted to determine factors related to survival. Propensity score matching method was implemented to balance patients' baseline characteristics. RESULTS: A total of 11 694 patients with Stage IV breast cancer at diagnosis met inclusion criteria. Surgical intervention occurred in 5202 patients (44.5%), with the use of surgery decreasing throughout the study period (53.6% surgery 2004-2006; 31.8% surgery 2011-2013). Selection for surgical intervention was associated with small tumors (T1) and a higher nodal burden (N2/3). Uninsured patients, those treated at academic centers, those treated in the Northeast, and those with hormone receptor positive tumors were less likely to undergo surgery. Surgery was independently associated with a better overall survival. Propensity score matching revealed a persistent survival advantage for surgical patients receiving surgery, regardless of the receipt of systemic therapy. CONCLUSIONS: Surgery on the intact primary tumor for patients presenting with de novo Stage IV breast cancer is associated with improved overall survival. Surgical resection in patients with Stage IV breast cancer should be considered for well-selected patients as a part of multimodality therapy.
BACKGROUND: Retrospective studies have shown some improvement in survival for patients receiving surgical management of the intact primary tumor in patients with presenting with Stage IV disease, while prospective studies have revealed mixed results. METHODS: An examination of the NCDB from 2004-2013 was undertaken to examine factors related to the utilization of surgery and overall survival in patients with de novo Stage IV disease. Univariate and multivariable analyses were conducted to determine factors related to survival. Propensity score matching method was implemented to balance patients' baseline characteristics. RESULTS: A total of 11 694 patients with Stage IV breast cancer at diagnosis met inclusion criteria. Surgical intervention occurred in 5202 patients (44.5%), with the use of surgery decreasing throughout the study period (53.6% surgery 2004-2006; 31.8% surgery 2011-2013). Selection for surgical intervention was associated with small tumors (T1) and a higher nodal burden (N2/3). Uninsured patients, those treated at academic centers, those treated in the Northeast, and those with hormone receptor positive tumors were less likely to undergo surgery. Surgery was independently associated with a better overall survival. Propensity score matching revealed a persistent survival advantage for surgical patients receiving surgery, regardless of the receipt of systemic therapy. CONCLUSIONS: Surgery on the intact primary tumor for patients presenting with de novo Stage IV breast cancer is associated with improved overall survival. Surgical resection in patients with Stage IV breast cancer should be considered for well-selected patients as a part of multimodality therapy.
Authors: J Ruiterkamp; M F Ernst; L V van de Poll-Franse; K Bosscha; V C G Tjan-Heijnen; A C Voogd Journal: Eur J Surg Oncol Date: 2009-04-26 Impact factor: 4.424
Authors: Z M Rashaan; E Bastiaannet; J E A Portielje; W van de Water; S van der Velde; M F Ernst; C J H van de Velde; G J Liefers Journal: Eur J Surg Oncol Date: 2011-10-26 Impact factor: 4.424
Authors: Jetske Ruiterkamp; Adri C Voogd; Koop Bosscha; Vivianne C G Tjan-Heijnen; Miranda F Ernst Journal: Breast Cancer Res Treat Date: 2009-12-13 Impact factor: 4.872
Authors: Lee Guek Eng; Shaheenah Dawood; Victoria Sopik; Benjamin Haaland; Pui San Tan; Nirmala Bhoo-Pathy; Ellen Warner; Javaid Iqbal; Steven A Narod; Rebecca Dent Journal: Breast Cancer Res Treat Date: 2016-09-14 Impact factor: 4.872